Mark Sullivan
Equibles does not estimate personal net worth.
Get an email with a short summary when Definium Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DFTX alertsAbout Mark Sullivan
The proxy statement of Definium Therapeutics, Inc. reports total compensation of $1,161,107 for Mark Sullivan in fiscal 2024, including a base salary of $439,750. Disclosed compensation is on record for 2 fiscal years. Definium Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Definium Therapeutics, Inc. includes Dr. Roger Crystal (CEO), Dr. Suzanne Bruhn (CEO), JR Rahn (CEO) and 7 others.
Affiliation history
-
Definium Therapeutics, Inc. (DFTX)
Proxy statement
CurrentStart not stated–present
Last confirmed April 27, 2026
Company network
Leadership on record at Definium Therapeutics, Inc.
- Dr. Roger Crystal CEO
- Dr. Suzanne Bruhn CEO
- JR Rahn CEO
- Robert Barrow CEO
- Stephen Hurst CEO
- Carol A. Vallone Chairman
- Brandi L. Roberts CFO
- David Gryska CFO
- Roger Adsett COO, Board Member
- Carrie F. Liao Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Definium Therapeutics, Inc. (DFTX) | J.D. Chief Legal Officer | $439,750 | $1,161,107 |
| 2023 | Definium Therapeutics, Inc. (DFTX) | J.D. Chief Legal Officer | $308,167 | $1,080,394 |
Recent activity
No call appearances or filed executive changes recorded yet.